(redirected from Megace)
Also found in: Dictionary, Medical.
Related to Megace: Megace ES
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for megestrol

a synthetic progestational compound used to treat endometrial carcinoma

References in periodicals archive ?
A new oral formulation of megestrol acetate has recently become commercially available, known as Megace ES.
Some people may experience side effects associated with Megace ES that include impotence, passing gas, rash, high blood pressure, fever, decreased libido, insomnia, upset stomach, and elevated blood sugar.
004 megace on Any [up arrow]: EPA 37% Meg 39% outcome Outcome Meg + EPA 45% ns of 10% weight LBM--NA gain in cancer Functional capacity--NA patients Quality of life--ns unrealistic Survival--ns Other--appetite [up arrow] EPA 63 Meg 69 Meg + epa 66 Moses et al.
We noted a recent report on a new formulation of Megace (megestrol acetate), an appetite stimulant, to improve its absorption [1]--and asked about the reputation of megace for putting on weight by increasing fat and water--not helpful when the problem is muscle wasting.
Megace blocks the effects of androgen, a male hormone, on breast cancer cells.
Because megace, an FDA-approved drug often prescribed for HIV-associated wasting, can cause significant, irregular vaginal bleeding in HIV-infected women, NIAID is planning a trial to assess an alternate drug, nandrolone, in women with HIV-associated weight loss.
In June, the company announced that it filed a Paragraph IV for the ANDA of Megace ES by Strativa Pharmaceuticals, a division of Par Pharmaceutical Inc.
Pharmaceutical company Par Pharmaceutical Companies Inc (NYSE:PRX) said on Wednesday that it is restructuring its branded division, Strativa Pharmaceuticals, to focus mostly on Megace ES and Nascobal.
In this issue of the Journal of Applied Research, Wanke and coworkers compare the effects of a concentrated formulation of megestrol acetate (Megace ES; Par Pharmaceutical, Spring Valley, NY) to conventional Megace in patients infected with HIV and losing weight on highly active antiretroviral therapy.
Emend by Merck in 2003, TriCor by Abbott in December 2004 and the most recent, Megace ES, by Par in July 2005;
After all that, I get the patient to sign on to 160 mg/day of Megace [megestrol], with a repeat curettage in 3 months.
7% in the second quarter, driven by reduced clinical development costs related to Megace ES.
In 2005 Par received approval for and introduced the appetite stimulant Megace ES (megestrol acetate) 625-mg/5-mL oral suspension, its first branded pharmaceutical product.
The new version will use the Megace trade name (which PRX has licensed from Bristol-Myers Squibb).